DiscoverMoneycontrol Podcast4833: Nifty at risk of further selloff below 25,050, Glenmark’s cancer drug deal and Polycab block deal | Market Minutes
4833: Nifty at risk of further selloff below 25,050, Glenmark’s cancer drug deal and Polycab block deal | Market Minutes

4833: Nifty at risk of further selloff below 25,050, Glenmark’s cancer drug deal and Polycab block deal | Market Minutes

Update: 2025-09-25
Share

Description

Indian markets are poised for a cautious start with the GIFT Nifty signaling a flat to mildly negative open. The Nifty failed to defend 25,100 on Wednesday amid broad-based weakness. Global cues remain mixed as Wall Street tech stocks face another round of selling and US Treasury yields edge higher, while investors await key economic data. Back home, Glenmark, Lupin and Polycab are among the stocks to watch out for today. We also track movements in oil, gold, plus other macro trends shaping sentiment. 

Tune in for all this and more in today’s Market Minutes — your morning podcast bringing you the top stories to kickstart your trading day, from stocks in the news to macro trends and global market cues.
Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

4833: Nifty at risk of further selloff below 25,050, Glenmark’s cancer drug deal and Polycab block deal | Market Minutes

4833: Nifty at risk of further selloff below 25,050, Glenmark’s cancer drug deal and Polycab block deal | Market Minutes

moneycontrol